Compound ID | 1898
Synonym(s): Lorabid | LY-163892
Class: Beta-lactam (cephalosporin, second generation)
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Binds to bacterial penicillin-binding proteins (PBP) and interferes with bacterial cell wall integrity and synthesis. Active against Gram-positive bacteria and against many Enterobacteriaceae; it is less vulnerable to extended-spectum beta-lactamases (ESBL) |
| Description: | Synthetic Cephalosporin (carbacephem). Oral application |
| Institute where first reported: | King Pharmaceuticals |
| Year first mentioned: | 1991 |
| Highest developmental phase: | Approved by FDA in 1991 |
| Development status: | Approved, off-patent , discontinued in many countries |
| Reason Dropped: | Discontinued in the US |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/5284585 |
| Guide to Pharmacology: | loracarbef |
| Citation: | https://pubmed.ncbi.nlm.nih.gov/8453172/ |